(177)Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition

(177)Lu-octreotate is an FDA-approved radionuclide therapy for patients with gastroenteropancreatic neuroendocrine tumours (NETs) expressing somatostatin receptors. The (177)Lu-octreotate therapy has shown promising results in clinical trials by prolonging progression-free survival, but complete res...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofving, Tobias, Sandblom, Viktor, Arvidsson, Yvonne, Shubbar, Emman, Altiparmak, Gülay, Swanpalmer, John, Almobarak, Bilal, Elf, Anna-Karin, Johanson, Viktor, Elias, Erik, Kristiansson, Erik, Forssell-Aronsson, Eva, Nilsson, Ola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391910/
https://www.ncbi.nlm.nih.gov/pubmed/30730850
http://dx.doi.org/10.1530/ERC-18-0509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391910/
https://www.ncbi.nlm.nih.gov/pubmed/30730850
http://dx.doi.org/10.1530/ERC-18-0509

Ejemplares similares